Sobi's head office is located at the Karolinska Institutet Science Park in Solna, Stockholm, Sweden
- Sobi is a leading integrated specialty and niche pharmaceuticals company dedicated to rare diseases.
- Revenues derive from product sales, and from manufacturing of and royalties from Refacto AF/Xyntha for Pfizer.
- Operations are organized in three business lines: Core Products, Partner Products and ReFacto Manufacturing.
- Our late stage pipeline includes three pivotal phase III programs within hemophilia and neonatology.
- The Sobi share is listed on NASDAQ OMX Stockholm (STO:SOBI).
| Key financials 2011 |
SEK M |
|
EUR M |
|
USD M |
| Net revenues |
1.911 |
|
212 |
|
294 |
| EBITA (before non-recurring items) |
127.3 |
|
14.1 |
|
19.6 |
| Net debt as of March 2012 |
178 |
|
20 |
|
27 |
| No. of employees |
500 |
|
500 |
|
500 |
Commercial presence
